Adcendo, ApS

Adcendo Denmark United Kingdom United States of America

05.01.2023 - 09:02:52

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality's DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC programAgreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers View original content:https://www.prnewswire.co.uk/news-releases/adcendo-aps-announces-license-agreement-with-duality-biologics-on-next-generation-adc-platform-301714100.html

@ prnewswire.co.uk